Bcl-xL
Bcl-xL, encoded by BCL2L1, is a major anti-apoptotic member of the BCL-2 family that regulates mitochondrial apoptosis through interactions with pro-apoptotic proteins and preservation of mitochondrial integrity[1][2]. Mechanistically, Bcl-xL suppresses mitochondrial outer membrane permeabilization, limits BAX/BAK activation, and modulates cellular bioenergetics, calcium signaling, and autophagy, linking survival pathways with metabolic adaptation under cellular stress[1][3]. Beyond canonical apoptosis control, Bcl-xL interacts with Beclin-1 and intracellular calcium regulators, including IP3 receptors and VDAC1, thereby influencing autophagy, endoplasmic reticulum-mitochondrial communication, and stress responses[1][4]. In disease models, elevated Bcl-xL expression promotes tumor cell survival, therapeutic resistance, angiogenesis, and metastatic progression across hematologic malignancies and solid tumors, including melanoma and breast cancer[1][5]. Compared with related BCL2L1 splice isoforms, Bcl-xL functions predominantly as a pro-survival protein, whereas the alternatively spliced Bcl-xS isoform exhibits pro-apoptotic activity, highlighting the biological significance of isoform-specific regulation in apoptosis research[2][6]. For experimental applications, Bcl-xL is a validated target of BH3 mimetics and other apoptosis-directed strategies, and its inhibition is widely used to investigate mitochondrial apoptotic priming, drug resistance mechanisms, and cancer cell dependency on anti-apoptotic signaling networks[1][7].
References:
- [1]. Silva JPN, et al. BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting. Int J Mol Sci. 2026;27(2):1123.
- [2]. Warren CFA, et al. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019 Feb 21;10(3):177. [Content Brief]
- [3]. Li M, et al. Bcl-XL: A multifunctional anti-apoptotic protein. Pharmacol Res. 2020;151:104547.
- [4]. Bcl-xL gene information from NCBI.
- [5]. Kim TJ, et al. Risk of Second Primary Malignancies among Patients with Early Gastric Cancer Exposed to Recurrent Computed Tomography Scans. Cancers (Basel). 2021 Mar 7;13(5):1144. [Content Brief]
- [6]. Chen W, et al. Alternative splicing of BCL-X and implications for treating hematological malignancies. Oncol Lett. 2021;22(4):670. [Content Brief]
- [7]. Campbell KJ, et al. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018;8(5):180002. [Content Brief]
-
Bcl-xL Related Products (123)
Related Products (123)
-
Antibodies (1)
-
IGF2BP1-IN-1
0 ImagesIGF2BP1-IN-1, a Cucurbitacin B (HY-N0416) derivative, is a potent IGF2BP1 inhibitor (KD = 2.88 nM). IGF2BP1-IN-1 binds directly to IGF2BP1, thereby inducing tumor cell cycle arrest, increasing apoptosis, and reducing autophagy. IGF2BP1-IN-1 can be used in research on NSLSC, colon, breast, liver, ovarian, pancreatic, and cervical cancers.
-
Navitoclax-piperazine
0 ImagesSynonyms: ABT-263-piperazineNavitoclax-piperazine (ABT-263-piperazine) is a Navitoclax (HY-10087) analog and BCL-XL inhibitor. Navitoclax-piperazine is the ligand for target protein of PROTAC DT2216 (HY-130604). Navitodax-pperaie and E3 ubiquitin ligase VHL ligand can be used to synthesize PROTAC DT2216 (HY-130604).
-
(R)-(-)-Gossypol
0 ImagesSynonyms: AT-101; R-(-)-gossypol acetic acid
-
Sorafenib (Standard)
0 ImagesSynonyms: Bay 43-9006 (Standard)Sorafenib (Standard) (Bay 43-9006 (Standard)) is the analytical standard of Sorafenib (HY-10201). This product is intended for research and analytical applications. Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
-
Anti-Mouse 4-1BB/CD137 Antibody (3H3)
0 ImagesCat. No.: HY-P99119Purity: 98.22%Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a κ agonistic monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer.
-
Sabutoclax
0 ImagesSynonyms: BI-97C1
-
(S)-Gossypol (acetic acid)
0 ImagesSynonyms: (S)-(+)-Gossypol acetic acid
-
XZ739
0 ImagesXZ739 is a potent and selective BCL-XL PROTAC degrader with a DC50 of 2.5 nM. XZ739 recruits CRBN to ubiquitinate and degrade BCL-XL via the ubiquitin-proteasome system. XZ739 also induces cell cycle arrest and caspase-mediated apoptosis. XZ739 can be used in research related to T-cell acute lymphoblastic leukemia and cholangiocarcinoma.
-
Caudatin
0 ImagesCaudatin is an orally active and brain-penetrant C-21 steroidal found in Cynanchum bungei decne with a variety of biological activities. Caudatin can inhibit cell proliferation, migration, invasion, cause cell phase arrest, induce apoptosis, autophagy, ROS prodution and loss of mitochondrial membrane potential. Caudatin activates PARP, caspase-3, -7, -9, upregulates pro-apoptotic Bad and Bax and downregulates anti-apoptotic Bcl-2 and Bcl-XL. Caudatin suppresses VEGF, FAK phosphorylation, upregulates p21, p27, DR5 protein expression, activates the p38 MAPK, JNK and PPARα/TFEB-mediated autophagy-lysosomal signaling pathways. Caudatin can be used for the research of cancer, inflammation and neurological disease, such as glioma and Alzheimer's disease.
-
PZ671
0 ImagesCat. No.: HY-174876Purity: 98.70%PZ671 is a Bcl-xL PROTAC degrader that recruits cereblon, with a DC50 of 0.9 nM in MOLT-4 T-ALL cells. PZ671 induces apoptosis via activation of caspase-3 and cleavage of PARP, and exhibits antitumor activity in T-cell acute lymphoblastic leukemia and small cell lung cancer models. PZ671 can be used for the research of T-cell acute lymphoblastic leukemia and small cell lung cancer.
-
PROTAC Bcl-xL degrader-2
0 ImagesPROTAC Bcl-xL degrader-2 is a selective Bcl-xL PROTAC degrader with a DC50 of 4.8 nM against Bcl-xL. PROTAC Bcl-xL degrader-2 forms a ternary complex with VHL E3 ligase, thereby redirecting the ubiquitin-proteasome system to mediate the degradation of Bcl-xL. PROTAC Bcl-xL degrader-2 triggers Apoptosis. PROTAC Bcl-xL degrader-2 can be used in the research of solid tumors and hematologic malignancies.
-
(R)-(-)-Gossypol acetic acid
0 ImagesSynonyms: AT-101 (acetic acid); (-)-Gossypol acetic acid; (R)-Gossypol acetic acid
-
PZ703b
0 ImagesPZ703b is a Bcl-xl PROTAC degrader that induces apoptosis and inhibits cancer cell proliferation. PZ703b can be used for the research of bladder cancer research.
-
A-385358
0 ImagesCat. No.: HY-16014CAS No.: 406228-55-5A-385358 is a selective inhibitor of Bcl-XL with Kis of 0.80 and 67 nM for Bcl-XL and Bcl-2, respectively.
